About Molecure S.A.
Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets to treat multiple incurable diseases.
Our extensive in-house expertise has allowed us to collaborate with top global academic research institutes to access untapped, novel biology targets.
We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the Flemish Institute for Biotechnology (VIB) in Ghent, the University of Michigan and the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science and technology.
Our most advanced in-house drug candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is expected to advance to Phase I/II clinical development in the second half of 2022.
In 2020 we signed an exclusive collaboration and license agreement with Galapagos for the global development and commercialization of OATD-01. OATD-01 (now GLPG4716) is a Phase II-ready chitotriosidase/acidic mammalian chitinase (CHIT1/AMCase) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases such as sarcoidosis.
Molecure’s headquarters and laboratories are located in Warsaw, with an additional laboratory facility in Łódź, Poland. The company is listed on the Warsaw Stock Exchange (ticker: MOC).
Our leadership team combines exceptional capabilities in medicinal chemistry and translational science with managerial experience and entrepreneurial attitude. We are passionate about exploring the unexplored.